Published Date: 13 Mar 2023
Italy: Treatment with SGLT2 inhibitors in patients with type 2 diabetes (T2D) is associated with a reduced risk of restenosis in the stent...
Read Full NewsClinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.
Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.
Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.
The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.
1.
Belzutifan Combo Could be Second-Line Option in Advanced RCC
2.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
3.
AI is useful in low-resource areas for triaging breast masses.
4.
After HSCT, a longer course of letermovir prophylaxis decreased the risk of cytomegalovirus infection.
5.
Effects of Recombinant Replacement Therapy Explained in Detailed Regarding Genetic Clotting Disorder.
1.
Improving TIVAP Use: Review of Standardization and Optimization Practices
2.
Debunking Myths About Systemic Mastocytosis: Separating Fact from Fiction
3.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
4.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
5.
CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
Navigating the Complexities of Ph Negative ALL - Part III
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation